Constipation is the most common gastrointestinal complaint in primary, acute, and long-term care settings in the United States. An estimated 42 million individuals in the United States have bowel issues or constipation. And an estimated 1 million have incontinence. For people with conditions that can require a bowel care program, such as spinal cord injury, Spina Bifida, Multiple Sclerosis, and Traumatic Brain Injury, a systematic approach to bowel management is recommended to prevent further health complications and maximize quality of life. With these conditions, and others, the product used for bowel care management must work quickly, effectively, and with little to no side effects. The active ingredient found in Enemeez® mini-enemas is docusate sodium. The Enemeez® formulation functions as a stool softening hyper-osmotic laxative by drawing water into the bowel from surrounding body tissues. The docusate sodium acts as a softener by preparing the stool to readily mix with watery fluids. The increased mass of stool promotes a bowel evacuation by stimulating nerve endings in the bowel lining and initiating peristalsis. Not only does it soften and loosen the stool, but it initiates a normal replicated stimulus. The Enemeez® mini-enema delivers 283mg of docusate sodium and functions as a stool softener hyper-osmotic laxative by drawing water into the bowel from surrounding body tissues, softening the stool and promoting a bowel movement. Enemeez® mini-enemas are used rectally and produce quick results, typically between 2-15 minutes, as opposed to hours or days for oral constipation medications.